Chronic rejection is the major cause of long-term heart allograft failure, characterized by tissue infiltration by recipient T cells with indirect allospecificity. Phosphoinositol-3-kinase p110δ is a key mediator of T cell receptor signaling, regulating both T cell activation and migration of primed T cells to non-lymphoid antigen-rich tissue. We investigated the effect of genetic or pharmacologic inactivation of PI3K p110δ on the development of chronic allograft rejection in a murine model in which HY-mismatched male hearts were transplanted into female recipients. We show that suppression of p110δ activity significantly attenuates the development of chronic rejection of heart grafts in the absence of any additional immunosuppressive treatment by impairing the localization of antigen-specific T cells to the grafts, while not inducing specific T cell tolerance. p110δ pharmacologic inactivation is effective when initiated after transplantation. Targeting p110δ activity might be a viable strategy for the treatment of heart chronic rejection in humans.
References
[1]
Tanaka M, Fedoseyeva EV, Robbins RC (2005) Graft coronary artery disease in murine cardiac allografts: proposal to meet the need for standardized assessment. JHeart Lung Transplant 24: 316–322.
[2]
Taylor DO, Edwards LB, Mohacsi PJ, Boucek MM, Trulock EP, et al. (2003) The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report--2003. JHeart Lung Transplant 22: 616–624.
[3]
Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, et al. (2009) Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 28: 1007–1022.
[4]
van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, et al. (2006) The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 114: 1599–1607.
[5]
Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, et al. (2001) Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. ProcNatlAcadSciUSA 98: 3276–3281.
Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, et al. (1996) Indirect recognition of donor HLA-DR peptides in organ allograft rejection. JClinInvest 98: 1150–1157.
[8]
Waaga AM, Gasser M, Laskowski I, Tilney NL (2000) Mechanisms of chronic rejection. CurrOpinImmunol 12: 517–521.
[9]
Chen Y, Demir Y, Valujskikh A, Heeger PS (2003) The male minor transplantation antigen preferentially activates recipient CD4+ T cells through the indirect presentation pathway in vivo. JImmunol 171: 6510–6518.
[10]
He C, Schenk S, Zhang Q, Valujskikh A, Bayer J, et al. (2004) Effects of T cell frequency and graft size on transplant outcome in mice. JImmunol 172: 240–247.
[11]
Huddleston SJ, Hays WS, Filatenkov A, Ingulli E, Jenkins MK (2006) CD154+ graft antigen-specific CD4+ T cells are sufficient for chronic rejection of minor antigen incompatible heart grafts. AmJTransplant 6: 1312–1319.
[12]
Schnickel GT, Whiting D, Hsieh GR, Yun JJ, Fischbein MP, et al. (2004) CD8 lymphocytes are sufficient for the development of chronic rejection. Transplantation 78: 1634–1639.
[13]
Sun H, Woodward JE, Subbotin VM, Kuddus R, Logar AJ, et al. (2002) Use of recombinase activation gene-2 deficient mice to ascertain the role of cellular and humoral immune responses in the development of chronic rejection. JHeart Lung Transplant 21: 738–750.
[14]
Szeto WY, Krasinskas AM, Kreisel D, Krupnick AS, Popma SH, et al. (2002) Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy. Transplantation 73: 1116–1122.
[15]
Valujskikh A, Zhang Q, Heeger PS (2006) CD8 T cells specific for a donor-derived, self-restricted transplant antigen are nonpathogenic bystanders after vascularized heart transplantation in mice. JImmunol 176: 2190–2196.
[16]
Billingham RE, Brent L, Medawar PB (1953) Actively acquired tolerance of foreign cells. Nature 172: 603–606.
[17]
Kawai T, Shimauchi H, Eastcott JW, Smith DJ, Taubman MA (1998) Antigen direction of specific T-cell clones into gingival tissues. Immunology 93: 11–19.
[18]
Marelli-Berg FM, Frasca L, Weng L, Lombardi G, Lechler RI (1999) Antigen recognition influences transendothelial migration of CD4+ T cells. JImmunol 162: 696–703.
[19]
Marelli-Berg FM, James MJ, Dangerfield J, Dyson J, Millrain M, et al. (2004) Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo. Blood 103: 3111–3116.
[20]
Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV (2003) Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. JExpMed 197: 643–656.
[21]
Jarmin SJ, David R, Ma L, Chai JG, Dewchand H, et al. (2008) T cell receptor-induced phosphoinositide-3-kinase p110delta activity is required for T cell localization to antigenic tissue in mice. JClinInvest 118: 1154–1164.
[22]
Sobel RA, Blanchette BW, Bhan AK, Colvin RB (1984) The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increases prior to inflammatory cell infiltration. J Immunol 132: 2402–2407.
[23]
Okkenhaug K, Vanhaesebroeck B (2003) PI3K in lymphocyte development, differentiation and activation. NatRevImmunol 3: 317–330.
[24]
Wang J, Auger KR, Jarvis L, Shi Y, Roberts TM (1995) Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. JBiolChem 270: 12774–12780.
[25]
Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE (1998) LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92: 83–92.
[26]
Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, et al. (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031–1034.
[27]
Soond DR, Bjorgo E, Moltu K, Dale VQ, Patton DT, et al. (2010) PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115: 2203–2213.
[28]
Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS (2002) Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. NatImmunol 3: 844–851.
[29]
Simpson E, Scott D, Chandler P (1997) The male-specific histocompatibility antigen, H-Y: a history of transplantation, immune response genes, sex determination and expression cloning. Annu Rev Immunol 15: 39–61.
[30]
Amano J, Ishiyama S, Nishikawa T, Tanaka H, Nagai R, et al. (1997) Proliferation of smooth muscle cells in acute allograft vascular rejection. J Thorac Cardiovasc Surg 113: 19–25.
[31]
Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, et al. (2004) Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 173: 2236–2240.
[32]
Kearney ER, Pape KA, Loh DY, Jenkins MK (1994) Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1: 327–339.
[33]
de Waal RM, Bogman MJ, Cornelissen IM, Vermeulen AN, Koene RA (1986) Expression of donor class I major histocompatibility antigens on the vascular endothelium of mouse skin allografts. Transplantation 42: 178–183.
[34]
de Waal RM, Bogman MJ, Maass CN, Cornelissen LM, Tax WJ, et al. (1983) Variable expression of Ia antigens on the vascular endothelium of mouse skin allografts. Nature 303: 426–429.
[35]
Marelli-Berg FM, Cannella L, Dazzi F, Mirenda V (2008) The highway code of T cell trafficking. JPathol 214: 179–189.
[36]
Manes TD, Pober JS (2008) Antigen presentation by human microvascular endothelial cells triggers ICAM-1-dependent transendothelial protrusion by, and fractalkine-dependent transendothelial migration of, effector memory CD4+ T cells. JImmunol 180: 8386–8392.
[37]
Christen T, Nahrendorf M, Wildgruber M, Swirski FK, Aikawa E, et al. (2009) Molecular imaging of innate immune cell function in transplant rejection. Circulation 119: 1925–1932.
[38]
Murase N, Ichikawa N, Ye Q, Chun HJ, Okuda T, et al. (1999) Dendritic cells/chimerism/alleviation of chronic allograft rejection. JLeukocBiol 66: 297–300.
[39]
Ozdemir BH, Sezgin A, Haberal M (2009) Apoptosis and proliferation of cardiomyocytes and interstitial mononuclear cells: association with rejection and macrophage infiltration. TransplantProc 41: 2890–2892.
[40]
Capla JM, Ceradini DJ, Tepper OM, Callaghan MJ, Bhatt KA, et al. (2006) Skin graft vascularization involves precisely regulated regression and replacement of endothelial cells through both angiogenesis and vasculogenesis. PlastReconstrSurg 117: 836–844.
[41]
Hasegawa S, Becker G, Nagano H, Libby P, Mitchell RN (1998) Pattern of graft- and host-specific MHC class II expression in long-term murine cardiac allografts: origin of inflammatory and vascular wall cells. AmJPathol 153: 69–79.
[42]
Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, et al. (2002) Chimerism of the transplanted heart. NEnglJMed 346: 5–15.
[43]
Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, et al. (2006) Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. ProcNatlAcadSciUSA 103: 19866–19871.
[44]
Scott D, Addey C, Ellis P, James E, Mitchell MJ, et al. (2000) Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens. Immunity 12: 711–720.
[45]
Millrain M, Chandler P, Dazzi F, Scott D, Simpson E, et al. (2001) Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. JImmunol 167: 3756–3764.
[46]
Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, et al. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733–747.
[47]
Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, et al. (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431: 1007–1011.
[48]
Xu Y, Chester AH, Hariri B, McCormack A, Sarathchandra P, et al. (2010) The indirect alloimmune response causes microvascular endothelial dysfunction-a possible role for alloantibody. Transplantation 90: 1157–1164.
[49]
Schwoebel F, Barsig J, Wendel A, Hamacher J (2005) Quantitative assessment of mouse skin transplant rejection using digital photography. Lab Anim 39: 209–214.
[50]
Mirenda V, Jarmin SJ, David R, Dyson J, Scott D, et al. (2007) Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 109: 2968–2977.
